Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease – a Swedish Gynecologic Cancer Group (SweGCG) study

References

• Heintz APM, Odicino F, Maisonneuve P, et al. Carcinoma of the Ovary. Int J Gynaecol Obstet. 2006;95S161–SS92.
   PubMed Web of Science ®Google Scholar
• Ataseven B, Chiva LM, Harter P, et al. FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited. Gynecol Oncol. 2016;142:597–607.
   PubMed Web of Science ®Google Scholar
• Köbel M, Kalloger SE, Huntsman DG, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29:203–211.
   PubMed Web of Science ®Google Scholar
• Cornelis S, Van Calster B, Amant F, et al. Role of neoadjuvant chemotherapy in the management of stage IIIC-IV ovarian cancer: survey results from the members of the European Society of. Int J Gynecol Cancer. 2012;22:407–416.
   PubMed Web of Science ®Google Scholar
• Fagö-Olsen C, Lindberg C, Ottesen B, et al. Differences in regional diagnostic strategies and in intended versus actual first-line treatment of patients with advanced ovarian cancer in Denmark. Int J Gynecol Cancer. 2014;24:1195–1205.
   PubMed Web of Science ®Google Scholar
• Shalowitz DI, Epstein AJ, Ko EM, et al. Non-surgical management of ovarian cancer: prevalence and implications. Gynecol Oncol. 2016;142:30–37.
   PubMed Web of Science ®Google Scholar
• Meyer LA, Cronin AM, Sun CC, et al. Use and effectiveness of neoadjuvant chemotherapy for treatment of ovarian cancer. J Clin Oncol. 2016;34:3854–3863.
   PubMed Web of Science ®Google Scholar
• Vergote IB, Nieuwenhuysen EV, Vanderstichele A. How to select neoadjuvant chemotherapy or primary debulking surgery in patients with stage IIIC or IV ovarian carcinoma. J Clin Oncol. 2016;34:3827–3828.
   PubMed Web of Science ®Google Scholar
• Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1–5.
   PubMed Web of Science ®Google Scholar
• Barlow L, Westergren K, Holmberg L, et al. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48:27–33.
   PubMed Web of Science ®Google Scholar
• Dahm-Kähler P, Borgfeldt C, Holmberg E, et al. Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG). Gynecol Oncol. 2017;144:167–173.
   PubMed Web of Science ®Google Scholar
• Rosenberg P, Kjølhede P, Staf C, et al. Data quality in the Swedish Quality Register of Gynecologic Cancer – a Swedish Gynecologic Cancer Group (SweGCG) study. Acta Oncol. 2017;22:1–8.
   Google Scholar
• Tavassoli F, Devilee P, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon (France): IARC Press; 2003.
   Google Scholar
• Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol. 2000;19:7–15.
   PubMed Web of Science ®Google Scholar
• Baek SJ, Park JY, Kim DY, et al. Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer. J Gynecol Oncol. 2008;19:223–228.
   PubMedGoogle Scholar
• Ferrandina G, Legge F, Petrillo M, et al. Ovarian cancer patients with ‘node-positive-only’ Stage IIIC disease have a more favorable outcome than Stage IIIA/B. Gynecol Oncol. 2007;107:154–156.
   PubMed Web of Science ®Google Scholar
• Onda T, Yoshikawa H, Yasugi T, et al. Patients with ovarian carcinoma upstaged to Stage III after systematic lymphadenctomy have similar survival to Stage I/II patients and superior survival to other Stage III patients. Cancer. 1998;83:1555–1560.
   PubMed Web of Science ®Google Scholar
• Paik ES, Lee YY, Lee EJ, et al. Survival analysis of revised 2013 FIGO staging classification of epithelial ovarian cancer and comparison with previous FIGO staging classification. Obstet Gynecol Sci. 2015;58:124–134.
   PubMedGoogle Scholar
• Rosendahl M, Hogdall CK, Mosgaard B. Restaging and survival analysis of 4036 ovarian cancer patients according to the 2013 FIGO classification for ovarian, fallopian tube and primary peritoneal cancer. Int J Gynecol Cancer. 2016;26:680–687.
   PubMed Web of Science ®Google Scholar
• Ataseven B, Grimm C, Harter P, et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecol Oncol. 2016;140:215–220.
   PubMed Web of Science ®Google Scholar
• Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–1259.
   PubMed Web of Science ®Google Scholar
• du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115:1234–1244.
   PubMed Web of Science ®Google Scholar
• Chiva L, Lapuente F, Castellanos T, et al. What should we expect after a complete cytoreduction at the time of interval or primary debulking surgery in advanced ovarian cancer? Ann Surg Oncol. 2016;23:1666–1673.
   PubMed Web of Science ®Google Scholar
• Nasioudis D, Chapman-Davis E, Frey MK, et al. Should epithelial ovarian carcinoma metastatic to the inguinal lymph nodes be assigned stage IVB? Gynecol Oncol. 2017 ;2017147:81–84.
   PubMed Web of Science ®Google Scholar